Showing 711-720 of 10544 results for "".
Cosmeceutical Science
https://practicaldermatology.com/topics/general-topics/cosmeceutical-science/19293/Patti Farris, MD discusses recent developments in cosmeceutical formulation with an emphasis on the latest research on ingredients like botanicals, growth factors, and peptides. She reviews the best evidence for cosmeceuticals and offers tips on product selection and use in a conversation with hostVaser Shape #2
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/-vaser-shape-2/19452/Slide show of the new Vaser Lipo System bullet pointing how it works, the advantages and the clinical results. Dramatic before and after photos are shown."Atopic Dermatitis in Diverse Skin Tones" Drs. Shahriari and Bhutani
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/atopic-dermatitis-in-diverse-skin-tones-drs-shahriari-and-bhutani/24542/Drs. Mona Shahriari and Tina Bhutani provide a comprehensive overview of managing atopic dermatitis (AD) in patients with skin of color, addressing unique challenges and considerations. To access the full video and more, join YoungMD Connect member for free 90-day trial with code Free90. Continue leSCALE 2024: Dr. Linda Stein Gold on Benzyne Release From Benzyl Peroxide
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-linda-stein-gold-benzyne-release-from-benzyl-peroxide/26373/Linda Stein Gold, MD, discusses the new information on benzyl peroxide and its implications at Music City SCALE.Mechanisms of Action for IL-17 Inhibition in Treating Psoriasis and Hidradenitis Suppurativa
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/mechanisms-of-action-for-il-17-inhibition-in-treating-psoriasis-and-hidradenitis-suppurativa/48808/Practical Dermatology Editorial Board member Jason E. Hawkes, MD, MS, FAAD, joins Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss articles from the Journal of Clinical Medicine and Clinics in Dermatology on how IL-17 inhibition is effective in treating psoriasis and hidradenitis suppurativa,New Meeting to Focus on Hair Loss, Scalp Conditions
https://practicaldermatology.com/videos/skin-minute/new-meeting-to-focus-on-hair-loss-scalp-conditions/56982/Practical Dermatology Editorial Board member Amy Spizuoco, DO, FAOCD, FAAD, previews the upcoming meeting that she co-founded, the DermVIP Summit, which will focus on hair loss and scalp conditions along with inflammatory skin diseases. The meeting will be held May 8-9 at the New York Academy of MedDermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaDWTV Extra: Remembering Dr. Robert Sidbury
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-remembering-dr-robert-sidbury/36520/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD; Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD; and Board Member Peter A. Lio, MD, FAAD, reflect on the life and career of their colleague Robert Sidbury, MD, MPH, who passed away suddenly at the age of 61.DermwireTV: Pharma Partnership Boosts Spesolimab, Plus More
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-pharma-partnership-boosts-spesolimab-plus-more/36519/In this episode of Dermwire TV, two pharma leaders partner to commercialize SPEVIGO for patients with generalized pustular psoriasis; interest in red light devices is up; and experts take a look at what’s new in psoriasis treatments on the Practical Dermatology Podcast.Evaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/videos/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin and